GV20 Therapeutics has received a milestone payment under its collaboration agreement with Mitsubishi Tanabe Pharma Corporation (MTPC). GV20 and MTPC entered into this collaboration in early 2025 to leverage GV20's antibodies, which are specifically directed against novel tumour antigen targets discovered through GV20's proprietary STEAD AI platform, to generate potentially first-in-class Antibody Drug Conjugates (ADCs).

"We are pleased to reach this milestone in our partnership with MTPC. This progress reflects our shared commitment to rapidly advancing innovative ADC therapies for patients with cancer. We look forward to continuing this positive momentum," said Ying Gong, PhD, Chief Business Officer, GV20.

Under the terms of the agreement, GV20 received an upfront payment and is eligible for milestone payments. MTPC received an exclusive right to negotiate a licence to these antibodies during the collaboration term.